Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. [electronic resource]
Producer: 20200921Description: 7202-7217 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis
- Autocrine Communication
- Biomarkers, Tumor -- metabolism
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Proliferation
- Drug Resistance, Neoplasm
- Fibroblast Growth Factor 1 -- metabolism
- Gene Expression Regulation, Neoplastic
- High-Throughput Screening Assays
- Humans
- Lung Neoplasms -- drug therapy
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- Melanoma -- drug therapy
- Mice
- Mice, Nude
- Prognosis
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 1 -- metabolism
- Survival Rate
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.